How to buy ProQR Therapeutics N-V stock

ProQR Therapeutics N.V is a biotechnology business based in the US. ProQR Therapeutics N-V shares (PRQR) are listed on the NASDAQ and all prices are listed in US Dollars.

ProQR Therapeutics N-V share price

Use our graph to track the performance of PRQR stocks over time.

ProQR Therapeutics N-V shares at a glance

• Key figures

Information last updated 2021-03-25.

52-week range	$3.60 - $7.54
50-day moving average	$4.99
200-day moving average	$4.60
Wall St. target price	$23.92
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.31

Buy ProQR Therapeutics N-V shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy ProQR Therapeutics N-V stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of ProQR Therapeutics N.V by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ProQR Therapeutics N-V financials

Revenue TTM	$11.3 million
Gross profit TTM	$9.5 million
Return on assets TTM	-24.49%
Return on equity TTM	-62%
Profit margin	0%
Book value	$1.36
Market capitalisation	$462.9 million

TTM: trailing 12 months

Shorting ProQR Therapeutics N-V shares

There are currently 1.2 million ProQR Therapeutics N-V shares held short by investors – that's known as ProQR Therapeutics N-V's "short interest". This figure is 29.3% up from 899,379 last month.

There are a few different ways that this level of interest in shorting ProQR Therapeutics N-V shares can be evaluated.

ProQR Therapeutics N-V's "short interest ratio" (SIR)

ProQR Therapeutics N-V's "short interest ratio" (SIR) is the quantity of ProQR Therapeutics N-V shares currently shorted divided by the average quantity of ProQR Therapeutics N-V shares traded daily (recently around 430674.07407407). ProQR Therapeutics N-V's SIR currently stands at 2.7. In other words for every 100,000 ProQR Therapeutics N-V shares traded daily on the market, roughly 2700 shares are currently held short.

However ProQR Therapeutics N-V's short interest can also be evaluated against the total number of ProQR Therapeutics N-V shares, or, against the total number of tradable ProQR Therapeutics N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ProQR Therapeutics N-V's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 ProQR Therapeutics N-V shares in existence, roughly 20 shares are currently held short) or 0.0287% of the tradable shares (for every 100,000 tradable ProQR Therapeutics N-V shares, roughly 29 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ProQR Therapeutics N-V.

Find out more about how you can short ProQR Therapeutics N-V stock.

ProQR Therapeutics N-V share dividends

We're not expecting ProQR Therapeutics N-V to pay a dividend over the next 12 months.

ProQR Therapeutics N-V share price volatility

Over the last 12 months, ProQR Therapeutics N-V's shares have ranged in value from as little as $3.6 up to $7.54. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ProQR Therapeutics N-V's is 0.4626. This would suggest that ProQR Therapeutics N-V's shares are less volatile than average (for this exchange).

ProQR Therapeutics N-V overview

ProQR Therapeutics N. V. , a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase 1/2 stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase 1/2 aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with General Hospital Corporation, Radboud University Medical Center, Inserm Transfert SA, and Leiden University Medical Center. ProQR Therapeutics N. V.

Frequently asked questions

What percentage of ProQR Therapeutics N-V is owned by insiders or institutions?
Currently 2.949% of ProQR Therapeutics N-V shares are held by insiders and 69.26% by institutions. When does the fiscal year end for ProQR Therapeutics N-V?
ProQR Therapeutics N-V's fiscal year ends in December. Where is ProQR Therapeutics N-V based?
ProQR Therapeutics N-V's address is: Zernikedreef 9, Leiden, Netherlands, 2333 Ck What is ProQR Therapeutics N-V's ISIN number?
ProQR Therapeutics N-V's international securities identification number is: NL0010872495 What is ProQR Therapeutics N-V's CUSIP number?
ProQR Therapeutics N-V's Committee on Uniform Securities Identification Procedures number is: N71542109